Therefore, FAM83H and SCRIB might be used as prognostic markers for CRC patients and as potential therapeutic targets for the poor prognostic population of CRC patients who have tumors that highly express FAM83H and SCRIB. This evidence concerns the gene SACK1H and colorectal carcinoma.